-+ 0.00%
-+ 0.00%
-+ 0.00%

Chardan Capital Initiates Coverage On Gossamer Bio with Buy Rating, Announces Price Target of $160

Benzinga·10/13/2026 19:31:44
Listen to the news
Chardan Capital analyst Andreas Argyrides initiates coverage on Gossamer Bio (NASDAQ:GOSS) with a Buy rating and announces Price Target of $160.